Medtronic Posts Strong Q3 2026 Growth on Cardiac and Diabetes Strength

Event summary

  • Medtronic reported Q3 FY26 revenue of $9.0 billion, up 8.7% year-over-year, with organic growth of 6.0%, exceeding guidance by 50 basis points.
  • Cardiac Ablation Solutions revenue surged 80%, driven by 137% U.S. growth in pulsed field ablation (PFA) portfolio.
  • Diabetes revenue increased 8.3%, led by double-digit international market growth.
  • Medtronic secured FDA clearance for Hugo robotic-assisted surgery and Stealth AXiS Surgical System for spinal procedures.
  • The company completed two M&A transactions: CathWorks in Coronary and Renal Denervation, and Anteris in Structural Heart.

The big picture

Medtronic's Q3 2026 results highlight the company's strategic focus on high-growth areas like cardiac ablation and diabetes management. The strong performance in these segments, coupled with regulatory approvals and M&A activity, positions Medtronic to capitalize on the increasing demand for advanced healthcare technologies. The company's ability to sustain this momentum will depend on its execution in integrating acquisitions and expanding its international footprint.

What we're watching

Innovation Pipeline
How Medtronic's recent regulatory approvals and M&A activity will accelerate its innovation pipeline and sustain long-term growth.
Market Expansion
Whether the strong international performance in Diabetes can be replicated in other segments to drive global growth.
Execution Risk
The pace at which Medtronic can integrate its recent acquisitions and leverage their technologies to enhance its portfolio.